These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, Peynircioglu B, Kabakci G. J Interv Cardiol; 2011 Feb; 24(1):77-84. PubMed ID: 20973822 [Abstract] [Full Text] [Related]
24. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients. Guo H, Wang J, Chen J, Shan J, Lee JD, Ueda T. Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758 [Abstract] [Full Text] [Related]
28. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes. Leal S, Galeote G, Jiménez-Valero S, Sánchez-Recalde A, Salinas P, Ruiz AS, Orbe LC, Dominguéz F, Moreno R, López-Sendón JL. Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474 [Abstract] [Full Text] [Related]
29. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Veselka J, Honek T. Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981 [Abstract] [Full Text] [Related]
34. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation. Malek LA, Chojnowska L, Klopotowski M, Maczynska R, Demkow M, Witkowski A, Kusmierczyk B, Piotrowicz E, Konka M, Dabrowski M, Ruzyllo W. Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395 [Abstract] [Full Text] [Related]
35. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy. Arslan F, Akdim F, Ten Berg JM. Catheter Cardiovasc Interv; 2021 Feb 15; 97(3):488-492. PubMed ID: 32808736 [Abstract] [Full Text] [Related]
37. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. Cavigli L, Fumagalli C, Maurizi N, Rossi A, Arretini A, Targetti M, Passantino S, Girolami F, Tomberli B, Baldini K, Tomberli A, Antoniucci D, Yacoub MH, Marchionni N, Stefano PL, Cecchi F, Olivotto I. Int J Cardiol; 2018 Dec 15; 273():155-161. PubMed ID: 30213605 [Abstract] [Full Text] [Related]
39. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience. Nogic J, Koh Y, Bak M, Gooley RP, Meredith IT, McCormick LM. Heart Lung Circ; 2018 Dec 15; 27(12):1446-1453. PubMed ID: 29129561 [Abstract] [Full Text] [Related]
40. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D. Eur J Echocardiogr; 2004 Oct 15; 5(5):347-55. PubMed ID: 15341870 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]